Acquisition context Aegerion Pharmaceuticals was acquired by Amryt Pharma in 2019, positioning Amryt as a growing commercial and development pipeline player in rare and orphan diseases, which can open cross-sell opportunities for Amryt's established and pipeline products.

Rare disease focus Amryt’s emphasis on rare and orphan diseases suggests sales opportunities with specialty pharmacies, patient advocacy groups, and payer programs seeking targeted therapies and access pathways for hard-to-till markets.

M&A momentum Notable acquisition activity by Chiesi in 2023 indicates potential integration of Amryt’s portfolio and strategic shifts; sales strategies should target complementary products, co-promotion opportunities, and channel realignment possibilities.

Financial footprint With revenue in the mid tens of millions and prior $125M financing history, there is a need for scalable market access and reimbursement strategies; leverage pricing, lifecycle management, and incentive programs to expand commercial footprint.

Strategic partnerships Amryt has a history of merging with and acquiring other biotech assets (e.g., Chiasma), presenting opportunities to propose collaboration on shared research, licensing, or co-development deals to accelerate market reach for rare disease therapies.